MARKET WIREBenzinga • 5d ago
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberghttps://www.bloomberg.com/news/articles/2026-10-27/congo-ebola-cases-top-10-000-as-violence-hits-health-workers
Why DCOY Stock surged +11.82% Today — RQD Quant Desk Flash
$1.23 +11.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.25
Decoy Therapeutics Inc. (DCOY) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $2.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.25 (+1.94%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DCOY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY DCOY SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (29% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (29% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.1 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.47-20.4% Next Q
53
Q2 (-2Q)Grade C-$1.17-17.1% Next Q
50
Q3 (-1Q)Grade D$0.97+26.8% Next Q
48
CurrentGrade D$1.23-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DCOY Turnaround Squeeze
While DCOY currently carries a cautious 45/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.16) and Max Pain ($1.29) forces dealer call-delta covering toward $49.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DCOY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DCOY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DCOY Stock surged +11.82% Today — RQD Quant Desk Flash
Decoy Therapeutics Inc. (DCOY) surged +11.82% to $1.23, trading at 2% of its 52-week range ($0.9 – $47.22). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.9 – $47.22) with RSI-14 at 34.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.23 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live DCOY Headlines & Catalysts
MARKET WIREBenzinga • 9d ago
'Africa at risk of continent-wide Ebola crisis, health chief warns' - Semaforhttps://www.semafor.com/article/10/23/2026/ebola-threat-was-underestimated-africa-cdc-chief-says
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DCOY)
- ✓Walkthrough of DCOY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DCOY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.67%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.21H $1.23L $1.05C $1.23VOL 116.9K
RES: $4.81SUP: $0.71SMA50: $2.16SMA200: $5.51
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DCOY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DCOY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DCOY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DCOY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DCOY)
Health Care Rank #492 of 1016
⚔️ CMND vs DCOY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DCOY vs. CMND, MBIO, JUNS, HCWB)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Decoy Therapeutics Inc. (DCOY) ranks #492 by composite RQD confidence (45/100, grade D) and #981 by equity capitalization ($2.9M). Within this direct 5-issuer industry benchmark cohort, DCOY leads on earnings valuation at N/A trailing P/E, while DCOY leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with DCOY at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DCOY
ACTIVE
Decoy Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +11.82% | $2.9M | Benchmark Subject |
| CMND Clearmind Medicine Inc. | D | 48/100 | — | — | — | -3.46% | $3.0M | /cmnd-vs-dcoy → |
| MBIO Mustang Bio Inc. | D- | 43/100 | — | — | -35.0% | +9.00% | $3.0M | /mbio-vs-dcoy → |
| JUNS Jupiter Neurosciences Inc. | E | 33/100 | — | 80.6% | -35.0% | -5.20% | $3.1M | /juns-vs-dcoy → |
| HCWB HCW Biologics Inc. | E | 27/100 | — | 20.0% | -35.0% | -3.28% | $2.6M | /hcwb-vs-dcoy → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001615219In its most recent audited fiscal period (FY2025, filed 2025-12-31), Decoy Therapeutics Inc. (DCOY) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $12.5M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (-6.7% YoY). On the balance sheet, DCOY closed FY2025 with $11.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $12.5M | -$4.8M | -$4.8M | $11.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $5.6M | -$4.5M | -$4.5M | $3.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $12.5M | -$12.8M | -$12.8M | — | — |
3. DCOY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DCOY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Decoy Therapeutics Inc. (NASDAQ: DCOY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.23 (+11.82% 1D, market cap $2.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DCOY ranks #492 in composite RQD confidence.
How does DCOY compare to CMND and MBIO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DCOY carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMND (Clearmind Medicine Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $3.0M) and MBIO (Mustang Bio Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M). Among the 5-stock peer group, DCOY leads on earnings multiple (N/A) while DCOY leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DCOY?
Per DCOY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001615219), Decoy Therapeutics Inc. generated $0 in revenue, $12.5M in net income, and -$4.8M in free cash flow against $11.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DCOY trading relative to its 50-day, 200-day, and 52-week technical levels?
DCOY last traded at $1.23 (+11.82% on volume of 56,609 shares), positioning the stock -43.06% below its 50-day simple moving average ($2.16) and -77.68% below its 200-day simple moving average ($5.51). Across its 52-week range of $0.90 to $47.22, DCOY sits at the 0.7% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.08 to $1.38).
DCOY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DCOY stock moving today?
Why DCOY Stock surged +11.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.